Alveolus Bio Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Later Stage VC
- Investors
-
5
Alveolus Bio General Information
Description
Developer of biotherapeutic delivery systems intended to address chronic lung diseases. The company's platform utilizes proprietary inhaled biotherapeutics that target fibroblast dysfunction and neutrophilic inflammation, enabling healthcare providers to improve patient outcomes in respiratory conditions such as chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
Contact Information
Website
www.alveolusbio.comCorporate Office
- 1500 1st Avenue North
- H102
- Birmingham, AL 35203
- United States
Corporate Office
- 1500 1st Avenue North
- H102
- Birmingham, AL 35203
- United States
Alveolus Bio Timeline
Alveolus Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 04-Aug-2025 | Completed | Clinical Trials - Phase 2 | |||
| 4. Accelerator/Incubator | 21-Nov-2024 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 15-Feb-2023 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 26-Oct-2021 | $4.5M | $4.5M | Completed | Pre-Clinical Trials | |
| 1. Spin-Off | 26-Oct-2021 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Alveolus Bio Patents
Alveolus Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022415443-A1 | Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease | Pending | 16-Dec-2021 | ||
| EP-4447951-A2 | Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease | Pending | 16-Dec-2021 | ||
| EP-4447951-A4 | Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease | Pending | 16-Dec-2021 | ||
| US-20250041214-A1 | Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease | Pending | 16-Dec-2021 | ||
| WO-2023114375-A2 | Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease | Inactive | 16-Dec-2021 | A61K9/0075 |
Alveolus Bio Signals
Alveolus Bio Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Shilpa Medicare | Corporation | Minority | ||
| Station 41 | Accelerator/Incubator | |||
| NIH Seed | Not-For-Profit Venture Capital | |||
| Biostack Ventures | Accelerator/Incubator | Minority | ||
| First Avenue Ventures | Accelerator/Incubator | Minority |
Alveolus Bio FAQs
-
When was Alveolus Bio founded?
Alveolus Bio was founded in 2020.
-
Where is Alveolus Bio headquartered?
Alveolus Bio is headquartered in Birmingham, AL.
-
What is the size of Alveolus Bio?
Alveolus Bio has 8 total employees.
-
What industry is Alveolus Bio in?
Alveolus Bio’s primary industry is Drug Discovery.
-
Is Alveolus Bio a private or public company?
Alveolus Bio is a Private company.
-
What is Alveolus Bio’s current revenue?
The current revenue for Alveolus Bio is .
-
How much funding has Alveolus Bio raised over time?
Alveolus Bio has raised $4.5M.
-
Who are Alveolus Bio’s investors?
Shilpa Medicare, Station 41, NIH Seed, Biostack Ventures, and First Avenue Ventures have invested in Alveolus Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process